Breast CancerPhase 1/2NCT01361945
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
A Phase 1/2 study testing AUY922 in people with Breast Cancer and Metastatic Breast Cancer, run by Texas Tech University Health Sciences Center, El Paso.
Trial summary
The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2 +. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer
- What is being tested?
- AUY922
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Jul 2011to Aug 2012
- Phase
- Phase 1/2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years
- Able to sign Informed Consent
- Patients must have the following laboratory values:
- Absolute Neutrophil Count (ANC) 1.5x109/L Hemoglobin (Hgb) 9 g/dl Platelets (plt) 100x109/L
- Potassium within normal limits
- Total calcium (corrected for serum albumin) and Phosphorus within normal limits
Show all 19Show fewer
- Magnesium above LLN or correctable with supplements
- AST/SGOT and ALT/SGPT ≤ 1.5 x Upper Limit of Normal (ULN) if AP > 2.5 ULN
- AST/SGOT and ALT/SGPT ≤ 2.5 x Upper Limit of Normal (ULN) if AP ≤ 5.0 x ULN if
- Serum bilirubin 1.5 x ULN
- Serum creatinin 1.5 x ULN or 24-hour clearance 50 ml/min
- Negative serum pregnancy test. The serum pregnancy test must be obtained prior to the first administration of AUY922 (≤ 72 hours prior to dosing) in all pre-menopausal women and women <2 years after the onset of menopause
- Histologically confirmed HER2 + and ER+ or PR + (i.e., HR+) Postmenopausal women with Metastatic breast cancer or resistant locally advanced breast cancer.
- Stage of disease (stage IIIb/c not responding or progressing to standard therapy with trastuzumab) or stage IV receiving first line treatment in the metastatic setting . All patients should have documented clinical progression prior to entering study
- Prior chemotherapy for metastatic stage IV disease is prohibited for patients enrolled in phase II, but allowed up to 3 lines for patients enrolled in Phase I. Prior neoadjuvant/adjuvant chemotherapy, antiestrogens, and radiotherapy are allowed. Adjuvant hormonal therapy including aromatase inhibitors are permitted in the adjuvant, neoadjuvant or metastatic setting if discontinued at least two weeks prior to starting study treatment. Trastuzumab is permitted in the adjuvant, neoadjuvant or metastatic setting if discontinued at least 4 weeks prior to study treatment
- Patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions and non-measurable disease are only evaluable for disease progression
- Patients must have tumors that carry HER-2 gene amplifications as determined by (i) fluorescence in situ hybridization (FISH) or (ii) overexpression of HER-2 protein 3+ level assessed by immunohistochemistry. Patients who have previously been treated with trastuzumab must be off treatment at least 6 weeks prior to starting study treatment.
- World Health Organization (WHO) Performance Status of < 1
- Life expectancy of > 12 weeks
Who cannot join
- Unresolved diarrhea ≥ CTCAE (v4.02) grade 1
- Pregnant or lactating women
- Impaired cardiac function, including any one of the following:
- History (or family history) of long QT syndrome
- Mean QTc ≥ 450 msec on baseline ECG
- History of clinically manifested ischemic heart disease ≤ 6 months prior to study start or History of heart failure or left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO or arrythmia
Show all 9Show fewer
- Patients known to be HIV positive. Testing is not required in the absence of clinical signs and symptoms suggesting HIV infection.
- Known hypersensitivity to any of the study drugs or their excipients
- Participation in another clinical study within 30 days before first study treatment
About this study
Official title: A Phase I/ II, Multi-center, Open-label Study, to Evaluate the Efficacy of AUY922 in Combination With Lapatinib With Letrozole in Postmenopausal Patients With Locally Advanced or Metastatic ER+ , HER2 + Breast Cancer
The purpose of this study is to find out what effects, administering infusions of AUY922 with hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients with advanced breast cancer known as ER+ HER2 +.
Read the detailed description
The dose and schedule of AUY922 is the MTD dose identified in the phase I, given as 1 hour infusion weekly.
The Phase II component will have a 2 stage design single arm design. (Section 9.0). Overall response rate (ORR) is the primary endpoint. Estimated N=40 (12 in first stage) .A total of 39 response-evaluable participants is required. In the first stage, 12 response-evaluable participants will be accrued; if there are 3 or fewer CR+PRs, the study will stop for futility. There is a 55% probability of stopping early if, in fact, the ORR is 28%. If there are 4 or more CR+PRs, the study will proceed to the second stage and an additional 27 response-evaluable participants will be accrued. We will accrue 1 additional patient (then the needed 39 to account for attrition)
- Conditions
- Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer
- Being tested
- AUY922
- Keywords
- ER+, HER2+, Breast
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AUY922Drug
Also called Intravenous drug
AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
| Study group | Role | What they receive |
|---|---|---|
| AUY922 | Experimental | Single Arm Receives: Drug: AUY922 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Response Rate
noted by tumor response using RECIST criteria
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2011 (estimated)
- Study startJul 2011
- Primary completionAug 2012
- Study completionAug 2012
Why it stopped: Closed due to no enrollment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Texas Tech University Health Sciences Center, El Paso
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeina Nahleh, Texas Tech University Health Sciences Center, El Paso
- Investigators
- Zeina Nahleh, M.D., Principal investigator, Texas Tech University Health Sciences Center, El Paso
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01361945
- Sponsor's protocol ID
- CAUY922ZN11
- Status last verified
- Dec 2015
- First submitted
- 24 May 2011
- Last updated
- 9 May 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: the study has not been completed